Current investigational drugs for major depression - Wikidata - awgldk - TriplyDB

Current investigational drugs for major depression

Current investigational drugs for major depression

http://www.wikidata.org/entity/Q28244223

about

Neurotoxins: free radical mechanisms and melatonin protection Vilazodone for the Treatment of Depression: An Update Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update SKF83959 is a novel triple reuptake inhibitor that elicits anti-depressant activity Brain Rewarding Stimulation Reduces Extracellular Glutamate Through Glial Modulation in Medial Prefrontal Cortex of Rats Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine Discovery and functional study of a novel crustacean tachykinin neuropeptide.Monoamine transporters: vulnerable and vital doorkeepers.Efficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials.Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited.Natural polyphenols in the management of major depression.Phototoxicity of herbal plants and herbal products.Triple monoamine uptake inhibitors.Five potential therapeutic agents as antidepressants: a brief review and future directions.Resting glutamate levels and rapid glutamate transients in the prefrontal cortex of the Flinders Sensitive Line rat: a genetic rodent model of depression.Investigations on agglomeration and haemocompatibility of vitamin E TPGS surface modified berberine chloride nanoparticles Criticisms of drugs in early development for the treatment of depression: what can be improved?Corticolimbic changes in acetylcholine and cyclic guanosine monophosphate in the Flinders Sensitive Line rat: a genetic model of depression.The andrologist's contribution to a better life for ageing men: part 2.5-Aminopyrazole as precursor in design and synthesis of fused pyrazoloazines.General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.

P2860

Q22305781-B84D07AA-81B3-4A30-A380-3E61700E60C8 Q26745605-46376422-4520-43D1-980C-23A469FB60CC Q28076712-1D554CB8-55B7-481B-9B6A-5A886EB5388B Q28295413-B6974715-A14F-486A-B565-C6C98F74627D Q30756186-15EEEF4B-37D2-4088-BCA3-E87A35C03297 Q34162662-D4F0E5FA-7252-433B-B0FA-78E85DBA6849 Q35661721-989F3664-1063-43B1-876A-46937A9CDF33 Q35877150-28A12220-724E-4D9F-81A4-5EE857EF95B9 Q36216847-1131C3BE-4824-4369-B29F-7AACE624F059 Q37891098-FA6363E1-2009-4845-9C1B-BDED4A4FD1FD Q38103949-916A8932-654C-4DB4-BD71-85B4139718D7 Q38136247-BE2BBB8B-4D49-4DDD-8D33-4F01BDA1193B Q38162938-3B99FCBB-E0A0-404A-86D6-3B8DD0856FB0 Q38574831-5F7167D4-7C85-46EC-86A5-2078A0892C8F Q39756450-1D8C97B7-D16E-4DE7-98EA-0E7D521DB047 Q41968953-A86B47E2-923F-47B0-B0EC-5910C6331019 Q48148268-CAA64A02-992E-4D96-A27B-78E895408259 Q48636177-4E21997C-AE64-43D7-877D-854CA4F784CE Q49170674-421540EC-02A0-4F07-8BF3-008AB3E91097 Q49489205-F2EFDDFF-C774-45C1-B239-43BA007BBA44 Q51509688-CD53336B-42DE-4F17-8981-2BA064D21386

P2860

Current investigational drugs for major depression

http://www.wikidata.org/entity/Q28244223

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Current investigational drugs for major depression

@ast

Current investigational drugs for major depression

@en

Current investigational drugs for major depression

@nl

type

label

Current investigational drugs for major depression

@ast

Current investigational drugs for major depression

@en

Current investigational drugs for major depression

@nl

prefLabel

Current investigational drugs for major depression

@ast

Current investigational drugs for major depression

@en

Current investigational drugs for major depression

@nl

P1433

Q28244223-11D58F19-5864-475D-98E9-CEAE8E6895B2

P1476

Q28244223-86BFA8AA-8CB5-42E5-BFE1-75B104F2D940

P2093

Q28244223-743C47C0-86ED-4EA0-869B-C69E3565B7D6

P2860

Q28244223-0245D57A-0981-48DB-B8AD-323AD94568A8

Q28244223-03F2B6DD-FC59-4198-8AE2-05147784C501

Q28244223-04D7F939-5282-4766-9A0B-BA1C656EA456

Q28244223-06803E82-E9D6-4416-A735-41667B2A8982

Q28244223-071166A2-4F6F-4140-908B-4A2401866111

Q28244223-07B9BC45-A2C1-4650-BACC-FFC64DB04226

Q28244223-0AAB18F0-8D4B-4132-82C9-1E9DC361BAE2

Q28244223-0CA4E693-0580-40D3-BDFD-1DF69CC93EE5

Q28244223-0D0202FC-4C7C-4E62-81DD-F9D9BBC63B6C

Q28244223-0E019362-9560-4CA6-B08A-AD6B0EF294E7

P304

Q28244223-7A305D36-905B-49CD-B87A-E680BE0DED7A

P31

Q28244223-76817388-89E4-4A60-B205-C7EDDCF6B98C

P3181

Q28244223-94A66441-1C60-4DAF-A12E-54C6B03D6EB6

P356

Q28244223-3EB58BB6-A47A-48B7-A30D-F603D3B4CA01

P407

Q28244223-CE9EBCCD-7FDD-4B29-8613-82862F92732D

P433

Q28244223-507C983A-6A4A-420D-81EC-3EA22E1892EE

P478

Q28244223-632628CC-CA0A-46BE-A555-02DAC1F8A513

P50

Q28244223-B72C5CD4-E54A-401E-B9A5-23E5D6563255

P577

Q28244223-2220FC2B-0B05-4D2C-A93D-9F11F31CF8A1

P698

Q28244223-D11100F6-FE97-4CCE-B1A1-56DB54E1B297

P3181

P356

13543780902880850

P1433

Expert Opinion on Investigational Drugs

P1476

Current investigational drugs for major depression

@en

P2093

Shrinivas K Kulkarni

http://www.w3.org/2001/XMLSchema#string

P2860

The novel cellular mechanism of human 5-HT6 receptor through an interaction with Fyn

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.

Regulating ankyrin dynamics: Roles of sigma-1 receptors

Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor

Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils

Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation

Triple uptake inhibitors: therapeutic potential in depression and beyond

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease

In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor

P304

767-88

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1464083

http://www.w3.org/2001/XMLSchema#string

P356

10.1517/13543780902880850

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19426122

http://www.w3.org/2001/XMLSchema#string